Larry B Goldstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1315487/publications.pdf

Version: 2024-02-01

323 papers 28,748 citations

72 h-index 164 g-index

326 all docs

326 docs citations

times ranked

326

23744 citing authors

#	Article	IF	Citations
1	Committee on Highâ€quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimer's and Dementia, 2022, 18, 1109-1118.	0.4	3
2	Risk Factors and Prevention., 2022, , 187-206.e6.		O
3	Advances in Stroke: Treatments-Preventive. Stroke, 2022, 53, 608-610.	1.0	2
4	Mechanical Thrombectomy Access for All? Challenges in Increasing Endovascular Treatment for Acute Ischemic Stroke in the United States. Journal of Stroke, 2022, 24, 41-48.	1.4	13
5	Disparities in Internet Use Among US Stroke Survivors: Implications for Telerehabilitation During COVID-19 and Beyond. Stroke, 2022, 53, STROKEAHA121037175.	1.0	3
6	Paradoxical Cerebral Air Embolism after Cardiac Ablation in Williams-Beuren Syndrome: A Clinico-Pathological Correlation. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106317.	0.7	1
7	Cardiovascular Risk Factor Profiles, Emergency Department Visits, and Hospitalizations for Women and Men with a History of Stroke or Transient Ischemic Attack: A Cross-Sectional Study. Journal of Women's Health, 2022, , .	1.5	1
8	Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory. Neurology, 2022, 98, 486-498.	1.5	46
9	Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage. Neurology, 2022, 99, .	1.5	9
10	Modern Medical Management of Acute Ischemic Stroke. Methodist DeBakey Cardiovascular Journal, 2021, 10, 99.	0.5	18
11	Neurologic complications of congenital heart disease in adults. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 15-22.	1.0	2
12	Screening for Asymptomatic Carotid Artery Stenosis. JAMA - Journal of the American Medical Association, 2021, 325, 443.	3.8	1
13	Treatments-Preventive. Stroke, 2021, 52, 1118-1120.	1.0	2
14	Amylin Dyshomeostasis Hypothesis: Small Vessel–Type Ischemic Stroke in the Setting of Type-2 Diabetes. Stroke, 2021, 52, e244-e249.	1.0	8
15	Development of a protocol to assess within-subject, regional white matter hyperintensity changes in aging and dementia. Journal of Neuroscience Methods, 2021, 360, 109270.	1.3	5
16	Contemporary Neuroscience Core Curriculum for Medical Schools. Neurology, 2021, 97, 675-684.	1.5	5
17	The association of circulating amylin with βâ€amyloid in familial Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12130.	1.8	21
18	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. Cerebrovascular Diseases, 2021, 50, 245-261.	0.8	32

#	Article	IF	Citations
19	Amylin-mediated regulation of LRP1 by miR-103/107 impairs \hat{l}^2 -amyloid efflux Alzheimer's and Dementia, 2021, 17 Suppl 3, e052576.	0.4	O
20	Amyloid- \hat{l}^2 removal from the brain is blocked by circulating amyloid-forming amylin secreted by the pancreas Alzheimer's and Dementia, 2021, 17 Suppl 3, e053782.	0.4	0
21	Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries. Kidney International, 2020, 97, 143-155.	2.6	31
22	Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease. Annals of Neurology, 2020, 87, 486-486.	2.8	10
23	Stroke in young cannabis users (18–49 years): National trends in hospitalizations and outcomes. International Journal of Stroke, 2020, 15, 535-539.	2.9	21
24	Reader response: Optimizing in-hospital triage for large vessel occlusion using a novel clinical scale (GAI2AA). Neurology, 2020, 95, 460.1-460.	1.5	0
25	It's Time to Revise the Uniform Determination of Death Act. Annals of Internal Medicine, 2020, 173, 75.	2.0	0
26	Reply. Journal of the American College of Cardiology, 2020, 76, 886-888.	1,2	2
27	Preserving stroke care during the COVID-19 pandemic. Neurology, 2020, 95, 124-133.	1.5	82
28	Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories. Journal of the American College of Cardiology, 2020, 75, 2110-2118.	1,2	27
29	Hierarchical Clustering Analyses of Plasma Proteins in Subjects With Cardiovascular Risk Factors Identify Informative Subsets Based on Differential Levels of Angiogenic and Inflammatory Biomarkers. Frontiers in Neuroscience, 2020, 14, 84.	1.4	7
30	Funds flow in academic neurology. Neurology, 2020, 94, 785-791.	1.5	8
31	Introduction for Focused Updates in Cerebrovascular Disease. Stroke, 2020, 51, 708-710.	1.0	19
32	Vascular Cellular Adhesion Molecule-1 (VCAM-1) and Memory Impairment in African-Americans after Small Vessel-Type Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104646.	0.7	8
33	Polypill Trials for Stroke Prevention—Main Results, Critical Appraisal, and Implications for US Population. Current Neurology and Neuroscience Reports, 2020, 20, 10.	2.0	1
34	Reader response: The dimension of preventable stroke in a large representative patient cohort. Neurology, 2020, 95, 557.2-558.	1.5	0
35	White Matter Hyperintensity Regression: Comparison of Brain Atrophy and Cognitive Profiles with Progression and Stable Groups. Brain Sciences, 2019, 9, 170.	1.1	20
36	Effect of Known Atrial Fibrillation and Anticoagulation Status on the Prehospital Identification of Large Vessel Occlusion. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104404.	0.7	6

#	Article	IF	CITATIONS
37	Absence of Motor-Evoked Potentials Does Not Predict Poor Recovery in Patients With Severe-Moderate Stroke: An Exploratory Analysis. Archives of Rehabilitation Research and Clinical Translation, 2019, 1, 100023.	0.5	5
38	Reader response: Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology, 2019, 92, 821.2-822.	1.5	0
39	Thrombolysis in young adults with acute ischemic stroke. Neurology, 2019, 92, 1129-1130.	1.5	3
40	Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association. Circulation, 2019, 139, e917-e936.	1.6	100
41	Hospital Quality Metrics: "America's Best Hospitals―and Outcomes After Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 430-434.	0.7	13
42	Development of a Non-invasive Device for Swallow Screening in Patients at Risk of Oropharyngeal Dysphagia: Results from a Prospective Exploratory Study. Dysphagia, 2019, 34, 698-707.	1.0	30
43	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e38-e81.	1.1	431
44	Increasing Stroke Knowledge and Decreasing Stroke Risk in a Latino Immigrant Population. Journal of Immigrant and Minority Health, 2018, 20, 1490-1499.	0.8	4
45	Advances in Stroke 2017. Stroke, 2018, 49, e174-e199.	1.0	21
46	Impact of Stroke Call on the Stroke Neurology Workforce in the United States: Possible Challenges and Opportunities. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2019-2025.	0.7	11
47	Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission. Stroke, 2018, 49, 2896-2903.	1.0	18
48	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid- \hat{l}^2 1-42 and Hypertension. Journal of Alzheimer's Disease, 2018, 66, 1095-1104.	1.2	21
49	Status epilepticus alert reduces time to administration of second-line antiseizure medications. Neurology: Clinical Practice, 2018, 8, 486-491.	0.8	9
50	Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid–eligible patients. Neurology, 2018, 91, e1553-e1558.	1.5	13
51	Twenty-First Century Cures Act. Stroke, 2018, 49, 2555-2558.	1.0	1
52	Randomized Sham-Controlled Trial of Navigated Repetitive Transcranial Magnetic Stimulation for Motor Recovery in Stroke. Stroke, 2018, 49, 2138-2146.	1.0	113
53	Revascularization for Acute Ischemic Stroke. , 2018, , 493-504.		0
54	Effect of Dextroamphetamine on Poststroke Motor Recovery. JAMA Neurology, 2018, 75, 1494.	4.5	23

#	Article	IF	Citations
55	BE-FAST (Balance, Eyes, Face, Arm, Speech, Time). Stroke, 2017, 48, 479-481.	1.0	121
56	Depression Status Is Associated with Functional Decline Over 1-Year Following Acute Stroke. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1393-1399.	0.7	20
57	Utility of Urgent Computed Tomography Angiography in the Setting of Intraparenchymal Brain Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 417-419.	0.7	0
58	Author response: Influence of sodium consumption and associated knowledge on poststroke hypertension in Uganda. Neurology, 2017, 88, 1103-1103.	1.5	0
59	Adverse Effects of Statins. JAMA - Journal of the American Medical Association, 2017, 317, 1079.	3.8	1
60	Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality. Stroke, 2017, 48, 327-334.	1.0	58
61	Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. Stroke, 2017, 48, 3245-3251.	1.0	19
62	Influence of Dietary Salt Knowledge, Perceptions, and Beliefs on Consumption Choices after Stroke in Uganda. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2935-2942.	0.7	8
63	Anticoagulation in Patients With Atrial Fibrillation in the Setting of Prior Hemorrhage. Stroke, 2017, 48, 2654-2659.	1.0	3
64	Brain microvascular injury and white matter disease provoked by diabetesâ€associated hyperamylinemia. Annals of Neurology, 2017, 82, 208-222.	2.8	52
65	Clinical Reasoning: Two see or not two see—Is it really double vision?. Neurology, 2017, 89, e56-e60.	1.5	0
66	Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks. Stroke, 2017, 48, 3223-3231.	1.0	28
67	Average Temperature, Diurnal Temperature Variation, and Stroke Hospitalizations. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1489-1494.	0.7	41
68	Screening for Asymptomatic Carotid Artery Stenosis. JAMA Internal Medicine, 2016, 176, 633.	2.6	3
69	Ischemic Stroke with Troponin Elevation: Patient Characteristics, Resource Utilization, and In-Hospital Outcomes. Cerebrovascular Diseases, 2016, 42, 213-223.	0.8	16
70	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio. Circulation, 2016, 133, e615-53.	1.6	36
71	Influence of sodium consumption and associated knowledge on poststroke hypertension in Uganda. Neurology, 2016, 87, 1198-1205.	1.5	9
72	IV tPA for acute ischemic stroke. Neurology, 2016, 87, 2178-2179.	1.5	4

#	Article	IF	CITATIONS
73	Accuracy of ICDâ€9 M Codes by Hospital Characteristics and Stroke Severity: Paul Coverdell National Acute Stroke Program. Journal of the American Heart Association, 2016, 5, .	1.6	39
74	Statins and poststroke intracerebral hemorrhage. Neurology, 2016, 86, 1570-1571.	1.5	2
75	Routine 24-Hour Computed Tomography Brain Scan is not useful in stable patients Post Intravenous Tissue Plasminogen Activator. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 540-542.	0.7	9
76	Development and Assessment of a Computer Algorithm for Stroke Vascular Localization Using Components of the National Institutes of Health Stroke Scale. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 281-287.	0.7	2
77	Video training and certification program improves reliability of postischemic neurologic deficit measurement in the rat. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 2203-2210.	2.4	8
78	Preventing a First Stroke., 2016, , 280-291.		1
79	Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke. Translational Stroke Research, 2015, 6, 430-436.	2.3	10
80	Neighborhood Socioeconomic Status and the Prevalence of Stroke and Coronary Heart Disease in Rural China: A Population-Based Study. International Journal of Stroke, 2015, 10, 388-395.	2.9	24
81	Centers for Medicare and Medicaid Services Medicare Data and Stroke Research. Stroke, 2015, 46, 598-604.	1.0	13
82	Treating In-Hospital Stroke. JAMA Neurology, 2015, 72, 1535.	4.5	2
83	Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients. Stroke, 2014, 45, 1429-1436.	1.0	74
84	Compliance With Acute Stroke Care Quality Measures in Hospitals With and Without Primary Stroke Center Certification: The North Carolina Stroke Care Collaborative. Journal of the American Heart Association, 2014, 3, e000423.	1.6	28
85	Lipids in High-Risk Patients Presenting With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2014, 45, 3180-3181.	1.0	3
86	Advances in Stroke. Stroke, 2014, 45, 371-372.	1.0	1
87	Temporal Changes in the External Validity of Clinical Trials: Asymptomatic Carotid Artery Stenosis. Cerebrovascular Diseases, 2014, 38, 174-175.	0.8	3
88	Out-of-Hospital Stroke Screen Accuracy in a State With an Emergency Medical Services Protocol for Routing Patients to AcuteÂStroke Centers. Annals of Emergency Medicine, 2014, 64, 509-515.	0.3	42
89	An assessment by the Statin Cognitive Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S5-S16.	0.6	92
90	Guidelines for the Primary Prevention of Stroke. Stroke, 2014, 45, 3754-3832.	1.0	1,621

#	Article	IF	Citations
91	Declining stroke mortality in young adults. Neurology, 2014, 83, 2102-2103.	1.5	2
92	Chronic Kidney Disease and Stroke. Advances in Chronic Kidney Disease, 2014, 21, 500-508.	0.6	39
93	Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. Stroke, 2014, 45, 2974-2982.	1.0	29
94	A Geographic Information System Analysis of the Impact of a Statewide Acute Stroke Emergency Medical Services Routing Protocol on Community Hospital Bypass. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2800-2808.	0.7	9
95	New Guidelines to Reduce Risk of Atherosclerotic Cardiovascular Disease. Stroke, 2014, 45, 945-947.	1.0	12
96	Prediction of Major Vascular Events after Stroke: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 778-784.	0.7	5
97	Screening for Asymptomatic Carotid Artery Stenosis: Caveat Emptor. Annals of Internal Medicine, 2014, 161, 370.	2.0	8
98	Epidemiology of Cerebrovascular Disease. , 2013, , 349-360.		1
99	"Code Stroke― Hospitalized versus Emergency Department Patients. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 345-348.	0.7	38
100	Death and Rehospitalization after Transient Ischemic Attack or Acute Ischemic Stroke: One-year Outcomes from the Adherence Evaluation of Acute Ischemic Stroke–Longitudinal Registry. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e181-e188.	0.7	24
101	Interventional and New Approaches to Stroke Prevention: Introduction. Stroke, 2013, 44, S37.	1.0	1
102	Forecasting the Future of Stroke in the United States. Stroke, 2013, 44, 2361-2375.	1.0	636
103	Interactions Within Stroke Systems of Care. Stroke, 2013, 44, 2961-2984.	1.0	175
104	Preventable Readmissions Within 30 Days of Ischemic Stroke Among Medicare Beneficiaries. Stroke, 2013, 44, 3429-3435.	1.0	109
105	Are Acute Stroke-Ready Hospitals Ready?. Stroke, 2013, 44, 3289-3291.	1.0	2
106	Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease. Stroke, 2013, 44, 2688-2693.	1.0	29
107	Seasonal Variation in 30-Day Mortality After Stroke. Stroke, 2013, 44, 531-533.	1.0	28
108	JURaSSiC. Neurology, 2013, 81, 448-455.	1.5	80

#	Article	IF	Citations
109	Statin Therapy Should be Discontinued in Patients With Intracerebral Hemorrhage. Stroke, 2013, 44, 2058-2059.	1.0	13
110	Stroke in sub-Saharan Africa: An urgent call for prevention. Neurology, 2013, 81, 403-404.	1.5	2
111	Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease [RETIRED]. Neurology, 2013, 80, 2065-2069.	1.5	86
112	Abstract TMP43: Ischemic Stroke Hospitalization Rates by State and Age. Stroke, 2013, 44, .	1.0	0
113	Depression and Antidepressant Use After Stroke and Transient Ischemic Attack. Stroke, 2012, 43, 1609-1616.	1.0	83
114	Regional Variation in Recommended Treatments for Ischemic Stroke and TIA. Stroke, 2012, 43, 1858-1864.	1.0	36
115	Letter by Goldstein Regarding Article, "Statins and Intracerebral Hemorrhage― Circulation, 2012, 125, e1015.	1.6	0
116	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. Stroke, 2012, 43, 3442-3453.	1.0	248
117	Advances in Prevention and Health Services Delivery 2010–2011. Stroke, 2012, 43, 298-299.	1.0	7
118	Long-Term Outcomes After Carotid Endarterectomy. Stroke, 2012, 43, 1197-1198.	1.0	1
119	30-Day Risk-Standardized Mortality and Readmission Rates After Ischemic Stroke in Critical Access Hospitals. Stroke, 2012, 43, 2741-2747.	1.0	51
120	Poststroke Hypertension in Africa. Stroke, 2012, 43, 3402-3404.	1.0	10
121	Letter by El Husseini et al Regarding Article, "What Causes Disability After Transient Ischemic Attack and Minor Stroke?― Stroke, 2012, 43, e180.	1.0	1
122	Poststroke Pharmacotherapy. Stroke, 2012, 43, 3433-3435.	1.0	3
123	Echocardiography for the Detection of Cardiac Sources of Embolism in Patients with Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 577-582.	0.7	26
124	Comparing the Use of Diagnostic Imaging and Receipt of Carotid Endarterectomy in Elderly Black and White Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 600-606.	0.7	14
125	Health-Related Quality of Life After Carotid Stenting Versus Carotid Endarterectomy. Journal of the American College of Cardiology, 2011, 58, 1557-1565.	1.2	147
126	Guidelines for the Primary Prevention of Stroke. Stroke, 2011, 42, 517-584.	1.0	1,289

#	Article	IF	Citations
127	Cerebral Magnetic Resonance Findings in Asymptomatic Patients After Atrial Fibrillation Catheter Ablation: Cause for Alarm or Further Study?. Journal of Cardiovascular Electrophysiology, 2011, 22, 969-972.	0.8	3
128	Poststroke Chronic Disease Management: Towards Improved Identification and Interventions for Poststroke Spasticity-Related Complications. International Journal of Stroke, 2011, 6, 42-46.	2.9	94
129	Similar Secondary Stroke Prevention and Medication Persistence Rates Among Rural and Urban Patients. Journal of Rural Health, 2011, 27, 401-408.	1.6	25
130	Novel platelet antiaggregants and the changing landscape of stroke prevention. Lancet Neurology, The, 2011, 10, 678-680.	4.9	5
131	Risk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic Syndrome. Archives of Neurology, 2011, 68, 1245.	4.9	91
132	Left atrial enlargement: A cause of stroke?. Cmaj, 2011, 183, 1129-1130.	0.9	4
133	Exploration of a Hypothesized Independent Association of a Common 9p21.3 Gene Variant and Ischemic Stroke in Patients with and without Angiographic Coronary Artery Disease. Cerebrovascular Diseases, 2011, 31, 117-122.	0.8	8
134	Concerns for the Reliability and Validity of the National Stroke Project Stroke Severity Scale. Cerebrovascular Diseases, 2011, 32, 426-430.	0.8	4
135	American Heart Association and Nonprofit Advocacy: Past, Present, and Future. Circulation, 2011, 123, 816-832.	1.6	20
136	Statins After Intracerebral Hemorrhage. Archives of Neurology, 2011, 68, 565-6.	4.9	10
137	Organizing the disorganized: improving TIA patient care. Nature Reviews Neurology, 2011, 7, 190-192.	4.9	0
138	Safety of Stenting and Endarterectomy by Symptomatic Status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke, 2011, 42, 675-680.	1.0	299
139	Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies. Stroke, 2011, 42, 2645-2650.	1.0	181
140	Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 30-38.	0.9	23
141	30-Day Mortality and Readmission After Hemorrhagic Stroke Among Medicare Beneficiaries in Joint Commission Primary Stroke Center-Certified and Noncertified Hospitals. Stroke, 2011, 42, 3387-3391.	1.0	81
142	Primary Prevention of Stroke., 2011,, 242-251.		0
143	Response to Letter by Martilnez-Salnchez et al. Stroke, 2010, 41, .	1.0	О
144	Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis, 2010, 29, 368-377.	1.0	8

#	Article	IF	CITATIONS
145	Stroke: Working toward a Prioritized World Agenda. International Journal of Stroke, 2010, 5, 238-256.	2.9	89
146	Statewide Hospital-Based Stroke Services in North Carolina. Stroke, 2010, 41, 778-783.	1.0	29
147	Stroke: Working toward a Prioritized World Agenda. Cerebrovascular Diseases, 2010, 30, 127-147.	0.8	25
148	Trends in One-Year Recurrent Ischemic Stroke among the Elderly in the USA: 1994–2002. Cerebrovascular Diseases, 2010, 30, 525-532.	0.8	53
149	Postendarterectomy Mortality in Octogenarians and Nonagenarians in the USA from 1993 to 1999. Cerebrovascular Diseases, 2010, 29, 154-161.	0.8	15
150	Geographic Variation in One-Year Recurrent Ischemic Stroke Rates for Elderly Medicare Beneficiaries in the USA. Neuroepidemiology, 2010, 34, 123-129.	1.1	43
151	Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke. Stroke, 2010, 41, 1051-1065.	1.0	46
152	Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease. Stroke, 2010, 41, 426-430.	1.0	47
153	Advances in Prevention and Health Services Delivery 2009. Stroke, 2010, 41, e71-3.	1.0	4
154	Stroke: Working Toward a Prioritized World Agenda. Stroke, 2010, 41, 1084-1099.	1.0	122
155	Differential Patterns of Cognitive Decline in Anterior and Posterior White Matter Hyperintensity Progression. Stroke, 2010, 41, 1946-1950.	1.0	42
156	What Is the Future of Stroke Prevention?. Stroke, 2010, 41, S35-8.	1.0	19
157	Distinctive RNA Expression Profiles in Blood Associated With White Matter Hyperintensities in Brain. Stroke, 2010, 41, 2744-2749.	1.0	54
158	Predictors of Hospital Readmission After Stroke. Stroke, 2010, 41, 2525-2533.	1.0	124
159	Physical activity and the risk of stroke. Expert Review of Neurotherapeutics, 2010, 10, 1263-1265.	1.4	19
160	Response to Letter Regarding Article, "Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal Hemorrhage: The Ibaraki Prefectural Health Study― Circulation, 2009, 120, .	1.6	0
161	The Complex Relationship Between Cholesterol and Brain Hemorrhage. Circulation, 2009, 119, 2131-2133.	1.6	7
162	The 2009 Feinberg Lecture. Stroke, 2009, 40, 3879-3882.	1.0	2

#	Article	IF	Citations
163	Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke, 2009, 40, 1405-1409.	1.0	215
164	Utilization of Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Are There Sex Differences?. Cerebrovascular Diseases, 2009, 27, 254-258.	0.8	27
165	Diagnostic Evaluation for Patients with Ischemic Stroke: Are There Sex Differences?. Cerebrovascular Diseases, 2009, 27, 450-455.	0.8	8
166	Lack of Impact of Paramedic Training and Use of the Cincinnati Prehospital Stroke Scale on Stroke Patient Identification and On-Scene Time. Stroke, 2009, 40, 754-756.	1.0	59
167	Poststroke Treatment. Stroke, 2009, 40, 8-9.	1.0	43
168	Advances in Primary Prevention and Health Services Delivery. Stroke, 2009, 40, e295-7.	1.0	3
169	Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke, 2009, 40, 2486-2492.	1.0	66
170	Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke, 2009, 40, 3526-3531.	1.0	120
171	Stroke Patient Outcomes in US Hospitals Before the Start of the Joint Commission Primary Stroke Center Certification Program. Stroke, 2009, 40, 3574-3579.	1.0	83
172	Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001–2004. Stroke, 2009, 40, 3845-3850.	1.0	66
173	Elderly Women Have Lower Rates of Stroke, Cardiovascular Events, and Mortality After Hospitalization for Transient Ischemic Attack. Stroke, 2009, 40, 2116-2122.	1.0	16
174	The Cart and The Horse. Circulation: Cardiovascular Interventions, 2009, 2, 153-155.	1.4	0
175	The American Heart Association's Principles for Comparative Effectiveness Research. Circulation, 2009, 119, 2955-2962.	1.6	39
176	The quest for the "Holy Grail" of ischemic stroke cytoprotection: Statins may not be the answer. Neurology, 2009, 73, 2058-2059.	1.5	3
177	JUPITER and the world of stroke medicine. Lancet Neurology, The, 2009, 8, 129-131.	4.9	7
178	Eating Yourself to a Stroke?. Annals of Neurology, 2009, 66, 129-131.	2.8	3
179	New data about stenting versus endarterectomy for symptomatic carotid artery stenosis. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 232-240.	0.4	9
180	Statins and ischemic stroke severity: Cytoprotection. Current Atherosclerosis Reports, 2009, 11, 296-300.	2.0	18

#	Article	IF	CITATIONS
181	Stroke-Related Knowledge among Uninsured Latino Immigrants in Durham County, North Carolina. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 229-231.	0.7	14
182	Dysnomia, Ataxia, Choreoathetosis, Sensory Impairment, and Gait Imbalance after Lentiform Nucleus Stroke. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 494-496.	0.7	6
183	The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal, 2009, 157, 428-435.e2.	1.2	37
184	Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis, 2009, 204, 515-520.	0.4	81
185	Predicting Aspiration in Patients With Ischemic Stroke. Chest, 2009, 135, 769-777.	0.4	142
186	Amphetamine Trials and Tribulations. Stroke, 2009, 40, S133-5.	1.0	29
187	Response to Letter by Bray and Bladin. Stroke, 2009, 40, .	1.0	0
188	Primary central nervous system vasculitis: Is biopsy appropriate?. Annals of Neurology, 2008, 64, 228-228.	2.8	7
189	How Much Can Be Gained by More Systematic Prevention of Stroke?. International Journal of Stroke, 2008, 3, 266-271.	2.9	10
190	Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1647-1652.	1.0	450
191	The American Heart Association's 2008 Statement of Principles for Healthcare Reform. Circulation, 2008, 118, 2209-2218.	1.6	53
192	Impact of Comorbidities on Ischemic Stroke Outcomes in Women. Stroke, 2008, 39, 2138-2140.	1.0	38
193	Reducing Death and Disability From Stroke. Stroke, 2008, 39, 2898-2901.	1.0	10
194	Should angioplasty and stenting be performed before CAGB in patients with asymptomatic carotid stenosis?. Nature Clinical Practice Neurology, 2008, 4, 250-251.	2.7	0
195	Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women. Stroke, 2008, 39, 2444-2448.	1.0	76
196	Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis. Stroke, 2008, 39, 3297-3302.	1.0	243
197	Advances in Prevention and Health Services Delivery 2007. Stroke, 2008, 39, 258-260.	1.0	19
198	Response to Letter by Mascitelli et al. Stroke, 2008, 39, .	1.0	0

#	Article	IF	Citations
199	10 Questions About Statins and Stroke. Neurologist, 2008, 14, 262-264.	0.4	O
200	Anticoagulation for atrial fibrillation in the elderly: part 1. Current Atherosclerosis Reports, 2008, 10, 284-5.	2.0	0
201	Minocycline treatment in acute stroke. Current Atherosclerosis Reports, 2008, 10, 286-7.	2.0	2
202	Acute Ischemic Stroke Treatment in 2007. Circulation, 2007, 116, 1504-1514.	1.6	81
203	Primary Prevention and Health Services Delivery. Stroke, 2007, 38, 222-224.	1.0	9
204	Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. Stroke, 2007, 38, 3198-3204.	1.0	302
205	Stroke Code Chest Radiographs Are Not Useful. Cerebrovascular Diseases, 2007, 24, 460-462.	0.8	5
206	Regulatory Device Approval for Stroke. Stroke, 2007, 38, 1737-1738.	1.0	2
207	Clinical trials report. Current Atherosclerosis Reports, 2007, 9, 258-260.	2.0	5
208	Statins for stroke prevention. Current Atherosclerosis Reports, 2007, 9, 305-311.	2.0	7
209	Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE trial. Current Atherosclerosis Reports, 2007, 9, 259-60.	2.0	0
210	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	1.0	1,510
211	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416
212	Can the ROSIER scale diagnose patients with stroke accurately in the emergency department?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 242-243.	3.3	1
213	The New Standing Guideline Committee Policy of the American Stroke Association Stroke Council. Stroke, 2006, 37, 753-753.	1.0	5
214	Response to Letter by Hart. Stroke, 2006, 37, 1966-1966.	1.0	0
215	Response to Letter by Mysak et al. Stroke, 2006, 37, 1968-1968.	1.0	0
216	Neurotransmitters and motor activity: Effects on functional recovery after brain injury. NeuroRx, 2006, 3, 451-457.	6.0	36

#	Article	IF	Citations
217	In utero exposure to nicotine and chlorpyrifos alone, and in combination produces persistent sensorimotor deficits and Purkinje neuron loss in the cerebellum of adult offspring rats. Archives of Toxicology, 2006, 80, 620-631.	1.9	56
218	Cough and Aspiration of Food and Liquids Due to Oral-Pharyngeal Dysphagia. Chest, 2006, 129, 154S-168S.	0.4	164
219	Advancing the Study of Stroke in Women. Stroke, 2006, 37, 2387-2399.	1.0	96
220	Diagnosis and Management of Cough Executive Summary. Chest, 2006, 129, 1S-23S.	0.4	677
221	Is There a Causal Relationship Between the Amount of Alcohol Consumption and Stroke Risk?. Stroke, 2006, 37, 1-2.	1.0	28
222	Advances in Primary Stroke Prevention. Stroke, 2006, 37, 317-319.	1.0	21
223	Improving the Clinical Diagnosis of Stroke. Stroke, 2006, 37, 754-755.	1.0	12
224	Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease. Stroke, 2006, 37, 1427-1431.	1.0	45
225	High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2006, 355, 549-559.	13.9	2,497
226	Primary Prevention of Ischemic Stroke. Stroke, 2006, 37, 1583-1633.	1.0	1,100
227	statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation,	1.6	156
228	ls simvastatin cost-effective for reducing the risk of vascular events?. Nature Clinical Practice Neurology, 2005, 1, 86-87.	2.7	0
229	Non-Atherosclerotic Vascular Disease in the Young. Journal of Thrombosis and Thrombolysis, 2005, 20, 93-103.	1.0	11
230	Lower stroke-related mortality in counties with stroke centers: North Carolina Stroke Facilities Survey. Neurology, 2005, 64, 762-763.	1.5	5
231	Recommendations for the Establishment of Stroke Systems of Care. Circulation, 2005, 111, 1078-1091.	1.6	189
232	Prevention and Health Services Delivery. Stroke, 2005, 36, 222-224.	1.0	0
233	Recommendations for the Establishment of Stroke Systems of Care. Stroke, 2005, 36, 690-703.	1.0	327
234	Guidelines for the Early Management of Patients With Ischemic Stroke. Stroke, 2005, 36, 916-923.	1.0	426

#	Article	IF	Citations
235	Neurologists' Evaluation and Treatment of Hyperhomocysteinemia in Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 101-106.	0.7	О
236	Is This Patient Having a Stroke?. JAMA - Journal of the American Medical Association, 2005, 293, 2391.	3.8	175
237	Blood Pressure Management in Patients With Acute Ischemic Stroke. Hypertension, 2004, 43, 137-141.	1.3	50
238	Statins for Secondary Stroke Prevention in Patients without Known Coronary Heart Disease: The Jury Is Still Out. Cerebrovascular Diseases, 2004, 18, 1-2.	0.8	15
239	Prevention and Health Services Delivery. Stroke, 2004, 35, 401-403.	1.0	1
240	Charlson Index Comorbidity Adjustment for Ischemic Stroke Outcome Studies. Stroke, 2004, 35, 1941-1945.	1.0	419
241	Co-exposure to pyridostigmine bromide, DEET, and/or permethrin causes sensorimotor deficit and alterations in brain acetylcholinesterase activity. Pharmacology Biochemistry and Behavior, 2004, 77, 253-262.	1.3	85
242	Seizures and Epilepsy After Ischemic Stroke. Stroke, 2004, 35, 1769-1775.	1.0	345
243	Neuroprotective therapy for acute ischaemic stroke: down, but not out. Lancet, The, 2004, 363, 414-415.	6.3	13
244	Task Force 5: Expert Testimony and Opinions. Circulation, 2004, 110, 2535-2537.	1.6	1
245	Screening for hypercoagulable syndromes following stroke. Current Atherosclerosis Reports, 2003, 5, 291-298.	2.0	12
246	Sensorimotor deficits and increased brain nicotinic acetylcholine receptors following exposure to chlorpyrifos and/or nicotine in rats. Archives of Toxicology, 2003, 77, 452-458.	1.9	27
247	Amphetamines and related drugs in motor recovery after stroke. Physical Medicine and Rehabilitation Clinics of North America, 2003, 14, S125-S134.	0.7	27
248	Neuropharmacology of TBI-induced plasticity. Brain Injury, 2003, 17, 685-694.	0.6	54
249	Transcranial doppler monitoring and clinical decision-making after subarachnoid hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 88-92.	0.7	21
250	Guidelines for the Early Management of Patients With Ischemic Stroke. Stroke, 2003, 34, 1056-1083.	1.0	1,037
251	American Heart Association Guide for Improving Cardiovascular Health at the Community Level. Circulation, 2003, 107, 645-651.	1.6	197
252	Model of Recovery of Locomotor Ability After Sensorimotor Cortex Injury in Rats. ILAR Journal, 2003, 44, 125-129.	1.8	26

#	Article	IF	Citations
253	MEDICINE: StroketPA and the Clinic. Science, 2003, 301, 1677-1677.	6.0	54
254	Veterans Administration Acute Stroke (VASt) Study. Stroke, 2003, 34, 999-1004.	1.0	56
255	Editorial Commentâ€"Prenatal Influences on Stroke Mortality in England and Wales. Stroke, 2003, 34, 1602-1603.	1.0	0
256	Editorial Comment—Advertising Strategies to Increase the Public Knowledge of the Warning Signs of Stroke. Stroke, 2003, 34, 1968-1969.	1.0	5
257	Extracranial Carotid Artery Stenosis. Stroke, 2003, 34, 2767-2773.	1.0	37
258	Statewide Assessment of Hospital-Based Stroke Prevention and Treatment Services in North Carolina. Stroke, 2003, 34, 2945-2950.	1.0	40
259	Prevention and Health Services Delivery. Stroke, 2003, 34, 367-369.	1.0	6
260	Pharmacotherapy in stroke rehabilitation. Advances in Neurology, 2003, 92, 447-50.	0.8	4
261	Differential Effects of Haloperidol and Clozapine on Motor Recovery after Sensorimotor Cortex Injury in Rats. Neurorehabilitation and Neural Repair, 2002, 16, 321-325.	1.4	47
262	Sensorimotor Deficit and Cholinergic Changes following Coexposure with Pyridostigmine Bromide and Sarin in Rats. Toxicological Sciences, 2002, 66, 148-158.	1.4	39
263	Physician Knowledge and Practices in the Evaluation of Coagulopathies in Stroke Patients. Stroke, 2002, 33, 948-953.	1.0	22
264	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation, 2002, 106, 388-391.	1.6	1,623
265	Telephone assessment of functioning and well-being following stroke: Is it feasible?. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 80-87.	0.7	8
266	Recommendations for Improving the Quality of Care Through Stroke Centers and Systems: An Examination of Stroke Center Identification Options. Stroke, 2002, 33, .	1.0	65
267	Contrast-Enhanced Magnetic Resonance Angiography of Carotid Arteries. Stroke, 2002, 33, 2834-2838.	1.0	65
268	Uranyl acetate-induced sensorimotor deficit and increased nitric oxide generation in the central nervous system in rats. Pharmacology Biochemistry and Behavior, 2002, 72, 881-890.	1.3	40
269	Utility of noninvasive studies in the evaluation of patients with carotid artery disease. Current Neurology and Neuroscience Reports, 2002, 2, 25-30.	2.0	6
270	Patient Safety in Trials of Therapy for Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2002, 287, 987-987.	3.8	0

#	Article	IF	Citations
271	Cost implications of specialized coagulation testing for acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2001, 10, 279-283.	0.7	6
272	Aptiganel Hydrochloride in Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2001, 286, 2673.	3.8	158
273	Primary Prevention of Ischemic Stroke. Stroke, 2001, 32, 280-299.	1.0	512
274	Retrospective Assessment of Initial Stroke Severity. Stroke, 2001, 32, 656-660.	1.0	149
275	Medical therapy for acute ischemic stroke. Current Atherosclerosis Reports, 2001, 3, 299-306.	2.0	3
276	Improving the Reliability of Stroke Subgroup Classification Using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Criteria. Stroke, 2001, 32, 1091-1097.	1.0	269
277	Primary Prevention of Ischemic Stroke. Circulation, 2001, 103, 163-182.	1.6	340
278	Locomotor and Sensorimotor Performance Deficit in Rats following Exposure to Pyridostigmine Bromide, DEET, and Permethrin, Alone and in Combination. Toxicological Sciences, 2001, 60, 305-314.	1.4	95
279	Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke. Stroke, 2000, 31, 3067-3078.	1.0	153
280	North Carolina Stroke Prevention and Treatment Facilities Survey. Stroke, 2000, 31, 66-70.	1.0	61
281	Novel risk factors for stroke: Homocysteine, inflammation, and infection. Current Atherosclerosis Reports, 2000, 2, 110-114.	2.0	12
282	Rehabilitation and recovery after stroke. Current Treatment Options in Neurology, 2000, 2, 319-328.	0.7	10
283	New Transient Ischemic Attack and Stroke. Archives of Internal Medicine, 2000, 160, 2941.	4.3	73
284	Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology, 2000, 39, 852-859.	2.0	86
285	Should Antihypertensive Therapies be Given to Patients with Acute Ischaemic Stroke?. Drug Safety, 2000, 22, 13-18.	1.4	15
286	Stroke-related knowledge among patients with access to medical care in the stroke belt. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 349-352.	0.7	13
287	Evidence-Based Medicine and Stroke. Neuroepidemiology, 1999, 18, 120-124.	1.1	10
288	Amphetamine-Facilitated Poststroke Recovery. Stroke, 1999, 30, 696-698.	1.0	19

#	Article	IF	CITATIONS
289	Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack. Stroke, 1999, 30, 1991-1994.	1.0	325
290	Clinical Stroke Trials. Stroke, 1999, 30, 1165-1166.	1.0	33
291	Age but not sex affects motor recovery after unilateral sensorimotor cortex suction-ablation in the rat. Restorative Neurology and Neuroscience, 1999, 15, 39-43.	0.4	4
292	Physician-reported readiness to change stroke prevention practices. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 358-363.	0.7	2
293	Multicenter Review of Preoperative Risk Factors for Endarterectomy for Asymptomatic Carotid Artery Stenosis. Stroke, 1998, 29, 750-753.	1.0	182
294	Potential Effects of Common Drugs on Stroke Recovery. Archives of Neurology, 1998, 55, 454.	4.9	167
295	North Carolina Stroke Prevention and Treatment Facilities Survey. Stroke, 1998, 29, 2069-2072.	1.0	30
296	Accuracy of ICD-9-CM Coding for the Identification of Patients With Acute Ischemic Stroke. Stroke, 1998, 29, 1602-1604.	1.0	377
297	Influence of common drugs and related factors on stroke outcome. Current Opinion in Neurology, 1997, 10, 52-57.	1.8	48
298	Effects of bilateral and unilateral locus coeruleus lesions on beam-walking recovery after subsequent unilateral sensorimotor cortex suction-ablation in the rat. Restorative Neurology and Neuroscience, 1997, 11, 55-63.	0.4	23
299	Effects of Dorsal Noradrenergic Bundle Lesions on Recovery After Sensorimotor Cortex Injury. Pharmacology Biochemistry and Behavior, 1997, 58, 1151-1157.	1.3	43
300	Reliability of the National Institutes of Health Stroke Scale. Stroke, 1997, 28, 307-310.	1.0	395
301	Health Status of Individuals With Mild Stroke. Stroke, 1997, 28, 740-745.	1.0	173
302	Primary Care Physician–Reported Secondary and Tertiary Stroke Prevention Practices. Stroke, 1997, 28, 746-751.	1.0	25
303	Complication Rates for Carotid Endarterectomy. Stroke, 1997, 28, 889-890.	1.0	47
304	Knowledge of Risk Among Patients at Increased Risk for Stroke. Stroke, 1997, 28, 916-921.	1.0	128
305	Retrospective Assessment of Initial Stroke Severity With the Canadian Neurological Scale. Stroke, 1997, 28, 1181-1184.	1.0	38
306	Sacral pseudoradiculopathy due to centrum semiovale stroke. Journal of Stroke and Cerebrovascular Diseases, 1996, 6, 41-44.	0.7	3

#	Article	IF	Citations
307	US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke, 1996, 27, 801-806.	1.0	26
308	US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Stroke, 1996, 27, 1473-1478.	1.0	16
309	Right vs. left sensorimotor cortex suction-ablation in the rat: no difference in beam-walking recovery. Brain Research, 1995, 674, 167-170.	1.1	18
310	Common drugs may influence motor recovery after stroke. Neurology, 1995, 45, 865-871.	1.5	231
311	Stroke Due to Recurrent Ipsilateral Carotid Artery Dissection in a Young Adult. Stroke, 1995, 26, 480-483.	1.0	38
312	Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke. Stroke, 1995, 26, 602-605.	1.0	172
313	US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke, 1995, 26, 1607-1615.	1.0	48
314	Rapid reliable measurement of lesion parameters for studies of motor recovery after sensorimotor cortex injury in the rat. Journal of Neuroscience Methods, 1993, 48, 35-42.	1.3	31
315	Basic and Clinical Studies of Pharmacologic Effects on Recovery from Brain Injury. Journal of Neural Transplantation & Plasticity, 1993, 4, 175-192.	0.7	74
316	Post-lesion administration of the NMDA receptor antagonist MK-801 does not impair motor recovery after unilateral sensorimotor cortex injury in the rat. Brain Research, 1992, 580, 129-136.	1.1	12
317	Norepinephrine depletion impairs motor recovery following sensorimotor cortex injury in the rat. Restorative Neurology and Neuroscience, 1991, 3, 41-47.	0.4	40
318	Post-lesion practice and amphetamine-facilitated recovery of beam-walking in the rat. Restorative Neurology and Neuroscience, 1990, 1, 311-314.	0.4	57
319	Beam-walking in rats: studies towards developing an animal model of functional recovery after brain injury. Journal of Neuroscience Methods, 1990, 31, 101-107.	1.3	138
320	Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. Brain Research, 1990, 508, 305-309.	1.1	90
321	Clinical use of Antiplatelet Agents in Cardiovascular Disease: Cerebrovascular Diseases. , 0, , 215-229.		0
322	Coagulopathy and Stroke. , 0, , 152-169.		1
323	Individual and Joint Effects of Influenza-Like Illness and Vaccinations on Stroke in the Young: A Case-Control Study: Can You Catch a Stroke?. Stroke, 0, , .	1.0	0